2: OT Roundup: MOGENRY data, RCA report, SYD-101, OCU410
Notes de l’épisode
Episode 2 of OT Roundup is here. Lucia Gambuzza and co-host Veeral Sheth, MD, break down 4-year durability data for MOGENRY in retinitis pigmentosa, RCA's first State of Retina Care report, the FDA's upcoming review of SYD-101 for pediatric myopia, and new Phase 2 data on OCU410 for geographic atrophy.
MOGENRY 4-year data: https://www.ophthalmologytimes.com/view/retina-society-2026-mco-010-optogenetic-therapy-maintains-visual-acuity-gains-through-4-years-in-advanced-rp
RCA's State of Retina Care report: https://www.ophthalmologytimes.com/view/rca-releases-first-state-of-retina-care-report
FDA Advisory Committee on SYD-101: https://www.ophthalmologytimes.com/view/fda-advisory-committee-syd-101-pediatric-myopia-october-30
Nimesh Patel, MD on pediatric progressive myopia: https://www.ophthalmologytimes.com/view/pediatric-progressive-myopia-epidemic-permanent-vision-loss
OCU410 Phase 2 data: https://www.ophthalmologytimes.com/view/retina-society-2026-medium-dose-ocu410-gene-therapy-cuts-geographic-atrophy-progression-up-to-32-in-phase-2-trial